In Difficult Times For AAV Gene Therapies, AbbVie Boosts Regenxbio’s Ambitions

Wet AMD Is Challenging Target

 
• By Andrew McConaghie
Regenxbio
Regenxbio has set out an ambitious goal of five gene therapies in pivotal trials or on the market by 2025 • Source: Alamy

More from Clinical Trials

More from R&D